We write to express our support for the proposed settlement with with Caremark Rx, L.L.C. and Zinc Health Services, LLC to highlight several provisions that will significantly improve affordability and access to medications for patients and propose critical enhancements to further strengthen the order’s protections.
Comments to Sen. Cassidy on 340B Drug Pricing Integrity and Affordability for Patients Act discussion draft
We submitted comments on the 340B for Patients Act discussion draft, supporting legislative efforts to put the 340B Program on a firm statutory basis so that it can continue to serve people affected by HIV and other serious conditions far into the future. We urge Congress to protect HIV, STD, and other safety-net providers as well as ADAPs, and oppose provisions that would restrict subgrantee eligibility for STD clinics. We support an updated patient definition that does not restrict telemedicine or rapid start interventions. We also strongly support new transparency, reporting, and affordability requirements for hospitals, which account for the vast majority of 340B spending and growth but face no requirements to demonstrate patient benefit.
Comments to CMS on their proposed rule to codify the Medicare price negotiation program
This rulemaking is the first opportunity to codify the Negotiation Program in binding regulatory text rather than annual sub-regulatory guidance, and codification is the appropriate moment to close these gaps. Patients were promised that this program would deliver meaningful affordability and access improvements, and CMS should use this rulemaking to make good on that promise through enforceable, not merely discretionary, standards. Our comments address patient engagement in the negotiation process, transparency in how patient input is used, formulary access and utilization management protections for selected drugs, and additional concerns about the negotiation methodology itself.
Response to Senate Finance Committee Democrat’s RFI on policy options to reduce drug prices
Drug-pricing policies should be evaluated based on whether they reduce what patients pay at the point of care without undermining access to treatment or the safety-net programs on which underserved communities rely.
Comments urging CMS administrator Oz to withdraw the Medicaid community engagement requirement for people living with HIV
Our comments focus on the rule’s narrowing of the medical frailty exclusion on people living with HIV. The rule requires states not just to determine if an enrollee has a serious or chronic medical condition, but also whether that condition “significantly impairs” their ability to work. This “significant impairment” standard is inconsistent with the statute, unworkable, and would harm people with HIV and stress the safety nets they rely on. We urge CMS to withdraw the rule and reissue it so as to make it compliant with the law.